chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Under recommended age for J&J vaccine. The facility has been requested to enter all COVID vaccines. The teams responsible for screening and administering vaccines to the refugees. Assisting with entering information into and VAERS.
12hr p/vax reports to Er large red swollen area lt thigh;RTC following day fro examine by MD rxn @ vax site;
The pt received Hep A vaccination on 05/06/2002 and developed urticarial rash (arms, legs, and trunk).
At 12 hour post vaccine a began feeling  achy. Within an hour I had chills and felt feverish. I went to bed. Woke up at 12:30 am on 12/11 and took my temp. 101.4 with a sweatshirt on.  Infection site arm is very sore. Overall I just feel really lousy. My husband is fine.
About 2 mins. after receiving the shot, I experienced a very rapid heartbeat; sensation like I could not swallow. It passed in about a minute.; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the right arm on 24Mar2021 at 17:15 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included none. The patient did not have any allergies to medications, food, or other products. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 17:17 about 2 mins after receiving the shot, the patient experienced a very rapid heart beat and sensation like the patient could not swallow. It passed in about a minute. No therapeutic measures were taken as a result of the events. The clinical outcome of the events rapid heart beat and sensation like the patient could not swallow were recovered on 24Mar2021.  No follow-up attempts are possible. No further information is expected.
Information has been received on 20-NOV-2018 regarding a case in litigation from a lawyer and a female patient of unknown age and her spouse. There was no information provided regarding the patient's concurrent conditions, past medical history or concomitant medications. In or around 06-DEC-2016, the patient was inoculated with ZOSTAVAX (lot number, expiration, dose and route unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving ZOSTAVAX, the patient suffered acute bronchitis, sudden idiopathic hearing loss in the patient's left ear secondary to microvascular disease, and erythematous skin patches. As a direct and proximate result of the ZOSTAVAX, the patient's symptoms have resulted in physical limitations not present prior to using ZOSTAVAX. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of the patient's condition. As a result of the ZOSTAVAX, the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of ZOSTAVAX, the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of ZOSTAVAX, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. Acute bronchitis, sudden idiopathic hearing loss in the patient's left ear secondary to microvascular disease, sudden idiopathic hearing loss in the patient's left ear secondary to microvascular disease and erythematous skin patches were considered to be disabling. Additional information was requested.
Information has been received from a patient's mother concerning a 19 year old female who was vaccinated with second of GARDASIL. The patient's mother reported that after the administration of the second dose (unknown date), her daughter experienced rash around the umbilical and tops of both thighs. The patient was taken to a dermatologist and was prescribed an unspecified topical cream. The mother stated that the cream did not improve the systems but that rash resolved "eventually" on an unknown date. On an unspecified date, the patient was vaccinated with the third dose of GARDASIL. The reporter said that the patient developed a similar rash, with the same distribution, after the third dose. The mother stated that the second occurrence of the rash developed "just recently" and at the time of the report had not been resolved. Additional information has been requested.
received a 3rd dose of Shingrix; This case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose in October 2020) and Shingrix (received 2nd dose in December 2020).   In February 2021, the patient received the 3rd dose of Shingrix. In February 2021, unknown after receiving Shingrix, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received 3rd dose of Shingrix, which led to extra dose administered, at their doctor's office, not the pharmacy.  No patient identifiers were provided except that it was a male patient.  The reporter stated that, there was a 2 months or greater interval between dose 1 and dose 2 of Shingrix.  No reactions were reported. The reporter consented to follow up.
I experienced some cold like symptoms. I went to the doctor and she said it might be a sinus problem. It turned out not to be a sinus problem. Then she thought I had allergies. I have been taking allergy medications and I don't think it has anything to do with allergies. I still have  cold like symptoms. I am still coughing and have congestion. It is not debilitating; I can still do my normal activities. I was tested for Covid when I went to the doctor and it was negative. 3 weeks after I went to the doctor I took a home Covid test and it was negative as well. If I continue to have these symptoms I will call them on Monday to make an appointment.
11:00 AM. Vaccine given. 11:10 AM - Pt complained of dizzy AND nausea. 11:28 - vitaLs TaKeN 11:43 - dizzy, nausea same 11:50 - complains of back itchiness 11:59 - vitals taken, no throat itchness  12:06 - Benadryl injection given 12:07 vitals taken, sleepy 12:15 PT husband picked Pt up.
missed his second Moderna vaccine due to cardiac surgery; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (missed his second Moderna vaccine due to cardiac surgery) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Surgery.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (missed his second Moderna vaccine due to cardiac surgery). At the time of the report, PRODUCT DOSE OMISSION ISSUE (missed his second Moderna vaccine due to cardiac surgery) outcome was unknown.            No concomitant medications reported. No treatment information was provided.
Information has been received from a physician referring to a 9 weeks old patient of unknown age. There was no medical history or concurrent condition reported. On 09-SEP-2015 the patient was vaccinated with VAQTA 25/0.5 (unit unknown) (lot # L013324, expiry date 24-APR-2017) (dosage and route were not reported) instead of RECOMBIVAX, for which the patient was indicated. At the time of the report, the patient had not demonstrated an adverse effect. Additional information has been requested.
Pain on injection and a few days after - this has subsided developed rash about 4 days after injection, started on shoulder around injection and has spread over shoulder and partly up neck. Advised to apply hydrocortisone 1% to rash and see doctor on Monday.
Woke up around midnight to following symptoms:  Fever of 102, Extreme Chills, Headache, Headache lingering behind eyeballs since vaccine, Extreme Body Ache, RACING heart rate, Lack of appetite  At around 8:15PM, when symptoms were not subsiding, I finally called advise nurse at Pfizer and my Insurance and was advised to go to the Emergency Room. I arrived at ER at 8:30PM
Information has been received from a pharmacist via company representative referring to an unspecified number of patients of unknown age and gender. No relevant medical history or concurrent conditions were reported. On unknown dates these patients were vaccinated with the first doses of ZOSTAVAX (lot#, expiration date, dose and route not reported). The reporting pharmacist stated, on unknown dates, an unspecified physician might be providing a booster dose of ZOSTAVAX (lot#, expiration date, dose and route not reported) to these patients after 5 years of receiving the initial doses. No adverse effects were reported. Additional information has been requested.
I got the 1st dose (027L20A IM, LA) and had just had a sore arm which lasted for 2 days. I got the 2nd dose vaccine, about 6 hours later, I had flu like symptoms- chills, migraines, fatigue and nausea. These symptoms lasted for 3 days and resolved. About a week later, I developed a rash. I had hives all over my body. My lips would swell up, the skin on my hands would swell and I could not lift or hold anything. It was very painful and itchy. I didn't take any medication until I saw my doctor. The doctor took blood work and tested me to see what I was allergic to. I was instructed to take an antihistamine (levocetirizine) once a day. I have been levocetirizine daily since February 2021 and it has improved my condition significantly. If I don't take my antihistamine, the symptoms are more intense. I still get random blotches on my skin and itchiness.
body aches and pains; Initial information received on 27-Apr-2020 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves a male patient who experienced body aches and pains (pain), while he received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE lot number not reported via unknown route for prophylactic vaccination.  On an unknown date, The patient developed a non-serious body aches and pains (pain) Unknown latency following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  No lab test reported.  Final diagnosis was body aches and pains.   It was not reported if the patient received a corrective treatment.  The patient outcome was not reported.  There will be no information available on the batch number for this case, currently.
Started getting the chills, a severe headache and fever of 101.3. Nausea the next day was unable to eat, chilling all day with a fever, extreme tiredness,  back pain, diarrrhea and eyes hurting, fever rising to 101.5.  Fever on Monday dropping to 99.9 and chilling with no energy. Tuesday back still hurts, no energy, had dark urine in the am. diarrhea in the afternoon. Lost 7 lbs.
covid-19; covid-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 04Apr2022 as dose 4 (booster), single (Lot number: FJ9943) at the age of 67 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "Thyroid" (unspecified if ongoing); "Psoriasis Arthritis" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Known allergies: acyclovir, reaction(s): "Allergy"; Known allergies: dicyclomine, reaction(s): "Allergy"; Known allergies: flagyl, reaction(s): "Allergy"; Known allergies: liothyronine, reaction(s): "Allergy"; Known allergies: nabumetone, reaction(s): "Allergy"; Known allergies: sulfasalazine, reaction(s): "Allergy". The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "covid-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 antibody test: (unspecified date) Unknown results, notes: Indication: Covid-19 treatment; (May2022) Positive, notes: Tested COVID positive 8, 9, and 11 days after Paxlovid; (May2022) Positive, notes: Tested COVID positive 8, 9, and 11 days after Paxlovid; (May2022) Positive, notes: Tested COVID positive 8, 9, and 11 days after Paxlovid. Therapeutic measures were taken as a result of drug ineffective, covid-19. Additional information: If vaccine received: Yes, Other medication in 2weeks: Yes. Adverse event: COVID rebound after Paxlovid series. Tested COVID positive 8, 9, and 11 days after Paxlovid and still feeling ill (13 days after end of series). Known allergies: Acyclovir, Dicyclomine, Flagyl, Liothyronine, Nabumetone, Sulfasalazine. Other medical history: Diabetes, Thyroid, Psoriasis Arthritis
My arm is tender to touch with slight bruising, red and swollen with a red rash spreading around the bi-sept muscle, and it has been 4 days since injection.
Information has been received from a medical assistant concerning a 66 year old female patient with arthritis, chronic back pain, hyperthyroidism and hypertension. Patient's drug reactions/allergies included DECADRON, inhaled steroids, BUSPAR, spectazole, scerzone, NORVASC, codeine, propranolol, erythromycin, prednisone, estradiol and methylpred. The patient on 30-SEP-2008 was vaccinated with a 0.5 ml dose of PNEUMOVAX (lot # 662020/0614X) intramuscularly. Concomitant therapy included influenza virus vaccine (unspecified) in opposite arm, CELEBREX, timolol maleate, felodipine, benazepril HCl, albuterol, MYCOLOG III, hydrochlorothiazide, SYNTHROID, omeprazole and estrogens, PREMARIX. On 02-OCT-2008 the patient experienced redness, swelling, itching an hot to touch at injection site. The patient sought medical attention. Subsequently, the patient recovered from these events "after 1 week". This is one of several reports received from the same source. Additional information has been requested.
Patient's spouse states patient had bruising and what looks like a possible infection. PCP was contacted on 6/6/12 and he stated he had no knowledge of the situation.
Well, the adverse event, it hurt a lot to breathe, they did a chest X-ray, was sent to a specialist, because my chiropractor noticed something on my X-ray's. I ended up in Emergency room because of pain. They did nothing for me. I went back to emergency room again because of pain, and I had a lump in my arm. I had a blood clot in arm, 2 blood clots. They gave me Xarelto and sent me home. I came back to ER for pain and was diagnosed with bone, liver, lung cancer. I have been in and out of the hospital.
This spontaneous  report as received from a nurse refers to a 22 year old female patient with headaches and migraines. Per reporter the patient had no pertinent medical history and no history of drug reactions/allergies. On 27-JAN-2014 the patient was vaccinated with an expired dose of GARDASIL (lot # 0849AA; expiry date 23-JUN-2013), 0.5 ml, intramuscularly. This was the patient's third dose of GARDASIL. Concomitant therapies included EXCEDRIN, ibuprofen, IMITREX and an unspecified birth control. After the patient received the third dose of GARDASIL, the patient became dizzy. The nurse reported that the patient sat and rested "for a second" after becoming dizzy and then "felt better". The patient outcome was reported as recovered. Additional information has been requested.
14hours p/recv vax pt exp chest & neck pain & SOB requiring ER visit; MD noted pt had fever up to 104; 9/23 pt recovered;
2:58PM PT STATES SHE 'BECAME WOOZY UPON STANDING UP; SAT DOWN IN CHAIR'. TALKING HER PHONE TO HER PCP. BP 140/70, HR 105, R 16, 02 SAT 99%. STATES SHE HASN'T EATEN MUCH TODAY. 3:05PM STATES SHE 'FEELS BETTER.' BP 120/62,  HR 91, R 16. LEFT WITH 2 FRIENDS. AMBULATORY - GAIT BRISK AND STEADY. NO OBVIOUS DISTRESS NOTED.
pt w/sz disorder controlled on Tegretol w/no sz for 2 1/2yr;Tegretol  level 7.4;had vax, awoke to generalized 5min sz;
pain at injection site left arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PAIN (pain at injection site left arm) in a 63-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INJECTION SITE PAIN (pain at injection site left arm). At the time of the report, INJECTION SITE PAIN (pain at injection site left arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. Treatment Medications were not provided by the reporter.
Received vaccination, immediately felt faint. laid down, legs elevated. Pt not sweating, pulse 130, not flushed. given H2O. 10 minutes later, pt states arms tingling, still feeling faint. Sent via wheelchair to nurse (school) to call parent.
Patient developed a rash at the injection site a few hours after and a day later developed non-itchy hives in the left under arm to the wrist.  Patient took 2 doses of diphenhydramine (over-the-counter) at the same time and the rash disappear the next day.  Patient at the 2nd injection time was clear of hives and rash in the left arm.
Pt had MVA and fractured left humerus and was given TD IM in ER on 2/28/02. He was admitted on 3/9/02 with febrile, aseptic meningitis and developed status epilepticus requiring intubation.
I woke up with post nasal drip and a sore throat. I thought it was just a cold. On Wednesday 25th I got tested for COVID, strep and flu. I came back COVID positive. I haven't had a fever the whole down. My oxygen has stayed the same. Mostly postnasal drip and sore throat. A little of a cough. I went to the urgent care.
this is an allergic reaction.; itchy scalp; This case was reported by a consumer via interactive digital media and described the occurrence of itchy scalp in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, less than a day after receiving Shingrix, the patient experienced itchy scalp and allergic reaction. On an unknown date, the outcome of the itchy scalp and allergic reaction were unknown.   It was unknown if the reporter considered the itchy scalp and allergic reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was selected as per the vaccine indication. The patient experienced an itchy scalp for about 2 hours the night of Shingrix vaccination. The patient asked did like to take the 2nd dose, but suppose this was an allergic reaction.  Should be hesitant.
Information has been received from a licensed practical nurse concerning a 15 year old female student who on 22-JAN-2007 was vaccinated intramuscularly in the left arm with a 0.5ml first dose of Gardasil (lot #653736/0868F). On 02-FEB-2007, it was discovered that the patient was pregnant. At the time of this report, the patient's last menstrual period was unknown. The patient sought unspecified medical attention and she was referred to an obstetrician/gynecologist. A pregnancy test was performed. On an unspecified date, the pregnancy was terminated. At the time of this report, the outcome was unknown. No product quality complaint was involved. Upon internal review, pregnancy was terminated was considered to be an other important medical event. Additional information is not expected.
Itchy in the area around the immunization; swelling in the area around the immunization; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION SITE PRURITUS (Itchy in the area around the immunization) and VACCINATION SITE SWELLING (swelling in the area around the immunization) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J2Q-2A) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (Itchy in the area around the immunization) and VACCINATION SITE SWELLING (swelling in the area around the immunization). At the time of the report, VACCINATION SITE PRURITUS (Itchy in the area around the immunization) and VACCINATION SITE SWELLING (swelling in the area around the immunization) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  No treatment was taken in response to the events.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient received pfizer vaccine on 08/18/2021  as his first dose for the covid vaccine series and for the second dose he received Moderna vaccine lot number 012H21B as his second dose of the vaccine series
Immunization Clinic calls at 3PM re 23 y/o Airman with onset of chest pain today around 1:30 PM s/p receipt of primary SPV with YF (live virus vaccines) yesterday morning (approx. 30 hours post-immunization). NP returns call to Airman and advises her to go to ED immediately for work-up and evaluation of new onset chest pain. She denies any prior personal cardiac history or any history of cardiac events in her immediate family at < 50 years of age. She is not a smoker. Her height is 72" and her weight is 200 lb.
shortly p/vax faintness, diaphoresis;improved p/several min;several min p/that trouble speaking, dysarthria;some words garbled sounding like was having trouble making certain sounds;had a h/a, BP 134/94;speech problems,v,slept 20-24hr;
low rubella titer; This spontaneous report was received from a female healthcare professional of unknown age who was referring to herself. No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On an unknown date, the was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (strength, dose, lot #, expiration date and route of administration were not provided) for immunization. The patient received dose when she was small and has no record of vaccination.  On an unknown date, the had low rubella titer (Rubella antibody negative). The outcome of the event was unknown. Action taken was not applicable.  The causal relationship between low rubella titer and measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) was unknown.